© 2000 European Society of Cardiology
Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats
Tokyo Medical College, 2nd Department of Internal Medicine Kunihiko Teraoka, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023, Tokyo, Japan
* Corresponding author. Tel.: +81-3-3342-6111, ext 5111; fax: +81-3-3342-4820. E-mail address: teraoka{at}tokyo-med.ac.jp (K. Teraoka)
 |
Abstract |
|---|
Cardiotoxicity is a limiting factor in the treatment of cancer with adriamycin. We administered adriamycin by a method which minimizes the risk of peritonitis in an adriamycin-induced cardiomyopathy rat model. Sixty male Wistar rats were given 1 mg/kg of adriamycin intraperitoneally 15 times over a 3-week period (total dose, 15 mg/kg) to induce the cardiomyopathy model. Fifteen control rats received 10 ml/kg body wt. saline 15 times over 3 weeks. The animals were observed for 12 weeks and assessed for mortality, and cardiac volume and function was analyzed by echocardiography at 4, 8, and 12 weeks. In rats treated with adriamycin, the cumulative mortality was 35.8% while in the controls, none of the rats died. Left ventricular diameter of the systole (LVDs) was significantly increased at 4 weeks (4.5 vs. 3.3 mm; P<0.001). Left ventricular diameter of the diastole (LVDd) was significantly increased at 12 weeks (7.9 vs. 7.0 mm; P<0.01) and the fractional shortening (FS) was significantly decreased at 8 weeks (33.4% vs. 50.0%; P<0.01) in the adriamycin-treated rats. This administration method appears to be useful for investigating the cardiac effect of adriamycin while avoiding the influence of peritonitis typically caused by an intraperitoneal injection of higher single doses of adriamycin.
Key Words: Heart failure • Animal studies
Received January 28, 2000; Revised March 10, 2000; Accepted June 20, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Y. Wonders, D. S. Hydock, C. M. Schneider, and R. Hayward Acute Exercise Protects Against Doxorubicin Cardiotoxicity Integr Cancer Ther, September 1, 2008; 7(3): 147 - 154. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Riad, S. Bien, M. Gratz, F. Escher, M. M. Heimesaat, S. Bereswill, T. Krieg, S. B. Felix, H. P. Schultheiss, H. K. Kroemer, et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice Eur J Heart Fail, March 1, 2008; 10(3): 233 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hamed, I. Barshack, G. Luboshits, D. Wexler, V. Deutsch, G. Keren, and J. George Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy Eur. Heart J., August 1, 2006; 27(15): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Simunek, I. Klimtova, J. Kaplanova, Y. Mazurova, M. Adamcova, M. Sterba, R. Hrdina, and V. Gersl Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents Eur J Heart Fail, June 1, 2004; 6(4): 377 - 387. [Abstract] [Full Text] [PDF]
|
|